静脈血栓塞栓症後の抗凝固薬の持続時間:メタ解析
David Ost1, Josh Tepper, Hanako Mihara
1Center for Pulmonary and Critical Care Medicine, North Shore University Hospital, Manhasset, NY 11030, USA. dost@nshs.edu
JAMA
|August 11, 2005
まとめ
延長された抗凝固薬は,再発性静脈血栓塞栓症 (VTE) のリスクを大幅に軽減します. 治療を中止した後も効果は持続しますが,保護効果は低下し,長期にわたる抗凝固薬が持続的なVTE保護を提供することを示しています.
科学分野:
- 心臓病学 心臓病学
- 血液学 ヘマトロジ
- クリニカル・メディシン 臨床医学
背景:
- 静脈血栓塞栓症 (VTE) の患者は,再発的なイベントのリスクが高い.
- VTEに対する抗凝固治療の最適な期間は,現在進行中の議論の対象となっています.
研究 の 目的:
- VTE患者における抗凝固治療期間延長に関する既存の証拠を体系的に検討する.
- 長期の抗凝固治療の比較リスクと利益を定量化するために.
主な方法:
- 主要なデータベース (PubMed,EMBase,Cochrane) と臨床試験登録簿を通じて,包括的な文献検索が行われました.
- 1969年から2004年の間に発表されたランダム化比較試験は,再発性VTEをアウトカムとして対象とした.
- データ抽出と品質評価は,2人の審査員によって独立して行われ,第三の審査員が意見の相違を判断した.
主要な成果:
- 延長された抗凝固薬は,短期治療 (IRR 0.21) と比較して,再発性VTEのリスクを有意に低下させた.
- 再発性VTEを予防する効果は,長期抗凝固薬の投与を中止した後でも,減少したが依然として有意であった (IRR 0.69).
- 重度の出血のリスクは,長期および短期抗凝固薬群の間で比較可能でした.
結論:
- 長期にわたる抗凝固薬は,治療期間中に再発性VTEから保護します.
- 再発性VTEに対する残留保護効果は,延長抗凝固薬の停止後に観察されます.
- この発見は,VTEの管理のために,有効性と安全性のバランスをとる拡張抗凝固剤の使用を支持します.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis I: Introduction
822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415


